Melissa Tada
Optometrist · Colorado Springs, CONPI 1154385169
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.7%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Coopervision Inc. accounts for 66.9% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2022 at $2,596 and has fallen 64.1% since, to $933 in 2025. Among optometrist clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 127 payments — averaging $70.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$6K
- Alcon$664
- Bausch & Lomb, A Division Of Bausch Health US, LLC$258
- Biotissue Holdings Inc.$243
- Sight Sciences, Inc.$222
- Kala Pharmaceuticals, Inc.$201
- plus $1K from 16 others
What the payments were for
- Speaking & faculty fees$1,51717%
- Travel & lodging$2,04723%
- Food & beverage$5,12758%
- Gifts$170%
- Entertainment$1842%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 55 | $5,952 |
| Alcon | 21 | $664 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $258 |
| Biotissue Holdings Inc. | 2 | $243 |
| Sight Sciences, Inc. | 3 | $222 |
| Kala Pharmaceuticals, Inc. | 5 | $201 |
| AbbVie | 5 | $156 |
| Optos, Inc. | 2 | $148 |
| Maculogix, Inc. | 2 | $134 |
| Shire North American Group Inc | 2 | $134 |
| Sun Pharmaceutical Industries Inc. | 5 | $127 |
| Lombart Brothers, Inc. | 1 | $99 |
| Optovue, Inc. | 2 | $96 |
| LKC Technologies, Inc. | 1 | $93 |
| Novartis | 4 | $84 |
| Bausch & Lomb Americas Inc. | 3 | $62 |
| Johnson & Johnson Vision Care, Inc. | 3 | $57 |
| Tarsus Pharmaceuticals, Inc. | 2 | $43 |
| Topcon Healthcare, Inc. | 1 | $35 |
| Oyster Point Pharma, Inc. | 1 | $33 |
| Eyevance Pharmaceuticals LLC | 2 | $31 |
| Carl Zeiss Meditec AG | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clariti Contact Lens$767
- Multiple Brands Contact Lens$750
- Non-Product Brand Specific$750
- MyDay Contact Lens$456
- PANORAMIC OPHTHALMOSCOPE$215
- OCT OPHTHALMOSCOPE$215
- BIOTRUE ONE DAY$215
- OMNI(R) SURGICAL SYSTEM (US)$144
- EYSUVIS$120
- MiSight Contact Lens$118
- DAILIES$118
- XIIDRA$109
- NFC-700$108
- BIOTRUE$107
- ULTRA$107
- Precision 1$105
How this compares
$8,891 in reported general payments places this provider in the 95th percentile of 1,025 optometrist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 19 | $23,384 |
| LumiganBimatoprost | 13 | $10,431 |
| Latanoprost | 14 | $175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $62 | $23,38419 claims |
| AbbVieLumigan | $156 | $10,43113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,025 optometrist providers in Colorado.
Other optometrist in Colorado Springs
- Justin ManningColorado Springs$13K
- Reed BroColorado Springs$8K
- Minon MitchellColorado Springs$8K
- Ryan BauerColorado Springs$6K
- Shane FrerichsColorado Springs$5K
- Leroy PopowskiColorado Springs$5K
- Cecelia KoettingAurora$458K
- Kaleb AbbottAurora$145K
- Joshua OlsonBoulder$80K
- Felicia PopowskiFt Carson$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.